Role of striatal dopamine in delayed neurotoxic effects of organophosphorus compounds.
Mipafox administered to rats daily for 35 days produced ataxia and a reduction in the level of dopamine in the corpus striatum. Treatment with Leptophos for the same period produced slight motor dysfunction and a small but significant reduction in the level of striatal dopamine. Fenitrothion neither produced motor dysfunction nor changed the level of striatal dopamine. The cholinesterase activity of corpus striatum was inhibited by all the compounds. The results suggest the possible involvement of striatal dopamine in the delayed neurotoxic effects of certain organophosphorus compounds.
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D003342:Corpus Striatum / Q000201:enzymology / Q000378:metabolism*; D005278:Fenitrothion / Q000494:pharmacology; D007531:Isoflurophate / Q000031:analogs & derivatives; D010773:Leptophos / Q000494:pharmacology; D008297:Male; D009048:Motor Skills / Q000187:drug effects; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D011437:Propylamines / Q000494:pharmacology; D051381:Rats
D002800:Cholinesterase Inhibitors; D009943:Organophosphorus Compounds; D011437:Propylamines; D007531:Isoflurophate; C005238:mipafox; D010773:Leptophos; D000110:Acetylcholinesterase; D005278:Fenitrothion